(Q43906641)

27 November 2017

title

Tamoxifen-induced endometrial changes in postmenopausal women with breast carcinoma (English)

1 reference

27 November 2017

1 reference

M Juneja

1

1 reference

27 November 2017

R Jose

2

1 reference

27 November 2017

A N Kekre

3

1 reference

27 November 2017

F Viswanathan

4

1 reference

27 November 2017

L Seshadri

5

1 reference

27 November 2017

publication date

1 March 2002

1 reference

International Journal of Gynecology and Obstetrics

27 November 2017

published in

1 reference

27 November 2017

volume

76

1 reference

27 November 2017

issue

3

1 reference

27 November 2017

page(s)

279-284

1 reference

Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2801%2900528-8

High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2801%2900528-8

Gynecologic effects of tamoxifen and the association with endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2801%2900528-8

Cancer of the uterine corpus after hormonal treatment for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2801%2900528-8

Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2801%2900528-8

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2801%2900528-8

Tamoxifen for breast cancer: associated endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2801%2900528-8

Uterine carcinosarcoma in association with tamoxifen therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2801%2900528-8

Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2801%2900528-8

Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2801%2900528-8

Tamoxifen as risk factor for carcinoma of corpus uteri

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2801%2900528-8

Long-term effects of adjuvant tamoxifen and/or radiotherapy. The South Sweden Breast Cancer Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2801%2900528-8

Uterine mullerian adenosarcoma following adenomyoma in a woman on tamoxifen therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2801%2900528-8

The role of ultrasound in the detection of endometrial pathologies in asymptomatic postmenopausal breast cancer patients with tamoxifen treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2801%2900528-8

Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2801%2900528-8

10.1016/S0020-7292(01)00528-8

7 January 2021

Identifiers

DOI

1 reference

27 November 2017

1 reference